Cybin Inc. (NASDAQ:HELP – Free Report) – Analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Cybin in a research note issued to investors on Monday, March 2nd. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($4.42) per share for the year, down from their prior estimate of ($3.02). HC Wainwright currently has a “Buy” rating and a $95.00 target price on the stock. HC Wainwright also issued estimates for Cybin’s Q4 2026 earnings at ($1.04) EPS, FY2027 earnings at ($3.04) EPS, FY2028 earnings at ($1.49) EPS, FY2029 earnings at $0.87 EPS and FY2030 earnings at $4.18 EPS.
Separately, Jefferies Financial Group assumed coverage on shares of Cybin in a research note on Monday, February 2nd. They issued a “buy” rating and a $22.00 price objective for the company. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $58.50.
Cybin Trading Up 8.0%
Shares of NASDAQ HELP opened at $8.53 on Thursday. The company has a market cap of $427.10 million, a price-to-earnings ratio of -2.02 and a beta of 0.61. Cybin has a one year low of $4.81 and a one year high of $9.83.
Cybin (NASDAQ:HELP – Get Free Report) last announced its quarterly earnings data on Friday, February 13th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.19).
Cybin Company Profile
Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.
The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.
Featured Articles
- Five stocks we like better than Cybin
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
